LH · Labcorp Holdings Inc.
$335.72
-1.96 (-0.58%)
At close · Aug 26
Market Cap
$27.40B
Shares
81.10M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$13.95B
+7.2%
FY2025
Net Income
$876.5M
+17.5%
FY2025
Gross Margin
28.76%
+0.9pp
FY2025
Operating Margin
9.92%
+1.6pp
FY2025
Diluted EPS
$10.46
+18.3%
FY2025
Operating Cash Flow
$1.64B
+3.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $14.35B | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B | $11.55B | $11.33B | $10.31B | $9.55B | $8.68B | $6.01B | $5.81B | $5.67B | $5.54B | $5B | $4.69B | $4.51B | $4.07B | |
| — | $10.2B | $9.94B | $9.38B | $8.8B | $8.16B | $8.14B | $9.03B | $8.3B | $8.16B | $7.22B | $6.7B | $5.78B | $3.81B | $3.59B | $3.42B | $3.27B | $2.91B | $2.72B | $2.63B | $2.38B | |
| — | $4.14B | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B | $3.25B | $3.18B | $3.09B | $2.85B | $2.9B | $2.2B | $2.22B | $2.25B | $2.27B | $2.1B | $1.97B | $1.87B | $1.69B | |
| — | — | 28.76% | 27.86% | 27.67% | 31.26% | 38.01% | 35.43% | 28.15% | 28.03% | 29.99% | 29.88% | 33.45% | 36.65% | 38.28% | 39.67% | 41.04% | 41.92% | 41.98% | 41.59% | 41.57% | |
| — | $2.22B | $2.22B | $2.23B | $2.02B | $1.76B | $1.69B | $1.73B | $1.62B | $1.57B | $1.5B | $1.35B | $1.63B | $1.2B | $1.13B | $1.11B | $1.16B | $1.03B | $958.9M | $935.1M | $808.7M | |
| — | $295.8M | $280M | $256.4M | $219.8M | $193.6M | $229.5M | $275.4M | $243.2M | $231.7M | $216.5M | $179.5M | $164.5M | $76.7M | $81.7M | $86.3M | $85.8M | $72.7M | $62.6M | $57.9M | $54.9M | |
| — | — | $681.1M | $643.5M | $577.3M | $537.2M | $577M | $624.7M | $577.2M | $552.1M | $533.2M | $499.2M | $457.8M | $245.5M | $230.1M | $229.8M | $231.4M | $203.6M | $195.1M | $179.7M | $162.8M | |
| — | — | — | — | $55.7M | $55.9M | $44.3M | $33M | $33.1M | $52.1M | $76M | $64.7M | $113.9M | $18.9M | $24.9M | — | — | — | $13.5M | $37.9M | $50.6M | |
| — | $1.5B | $1.38B | $1.09B | $725.6M | $1.44B | $3.05B | $2.45B | $1.33B | $1.33B | $1.31B | $1.27B | $996.8M | $910.4M | $990.9M | $1.02B | $948.4M | $978.8M | $935.9M | $842.9M | $777M | |
| — | — | 9.92% | 8.35% | 5.97% | 12.11% | 23.21% | 17.49% | 11.51% | 11.7% | 12.66% | 13.3% | 11.48% | 15.14% | 17.06% | 18.05% | 17.11% | 19.56% | 19.94% | 18.71% | 19.1% | |
| — | — | $2.07B | $1.73B | $1.3B | $1.97B | $3.63B | $3.07B | $1.91B | $1.88B | $1.84B | $1.77B | $1.45B | $1.16B | $1.22B | $1.25B | $1.18B | $1.18B | $1.13B | $1.02B | $939.8M | |
| — | $227.2M | $224.1M | $208.3M | $199.6M | $179.8M | $211.8M | $207.4M | $240.7M | $244.2M | $235.1M | $219.1M | $274.9M | $109.5M | $96.5M | $94.5M | $87.5M | $70M | $62.9M | -$72M | -$56.6M | |
| — | -$37.9M | -$55M | $60.2M | $15.5M | -$32.2M | $15.5M | -$226.3M | -$225.3M | -$57.4M | -$227.7M | -$197M | -$270.8M | -$83.7M | -$75.3M | -$79.3M | -$82.3M | -$4.9M | -$3.8M | -$2.1M | -$1.4M | |
| — | -$22.6M | -$13.3M | -$1.4M | -$1.4M | $5.4M | $26.5M | $2.9M | $9.8M | $11.6M | $11.3M | $7.9M | $10M | $14.3M | $16.9M | $21.4M | $9.5M | $10.6M | $13.8M | $14.4M | $77.9M | |
| — | $230.2M | $229.8M | $212.4M | $188.5M | $233.9M | $690M | $662.1M | $280M | $384.4M | -$155.4M | $360.7M | $287.3M | $314.1M | $340.2M | $359.4M | $333M | $344M | $329M | $307.9M | $325.5M | |
| — | $1B | $876.5M | $746M | $418M | $1.28B | $2.38B | $1.56B | $823.8M | $883.7M | $1.23B | $711.8M | $437.6M | $511.2M | $573.8M | $583.1M | $519.7M | $558.2M | $543.3M | $464.5M | $476.8M | |
| — | — | 6.28% | 5.73% | 3.44% | 10.78% | 18.1% | 11.13% | 7.13% | 7.8% | 11.9% | 7.45% | 5.04% | 8.5% | 9.88% | 10.28% | 9.38% | 11.16% | 11.57% | 10.31% | 11.72% | |
| — | $1.2M | $1.2M | $1.1M | $1.2M | $1.5M | $2.2M | $900K | $1.1M | $200K | $5.8M | $1.1M | $1.1M | $1.4M | $1.6M | $1.7M | $13.4M | $13.4M | $12.3M | $13.3M | $0 | |
| — | $935M | $1.11B | $543.7M | $613.9M | $977.8M | $2.35B | $1.77B | $914.5M | $754.3M | $1.48B | $416.9M | $161.1M | $434.5M | $570.6M | $607M | $476.7M | $585.2M | $621.5M | $327.8M | $538.1M | |
| USD/shares | — | — | $10.54 | $8.89 | $4.80 | $14.05 | $24.60 | $13.74 | $7.23 | $7.48 | $10.30 | $5.96 | $3.81 | $5.18 | $5.46 | $5.23 | $4.47 | $4.66 | $4.35 | $3.63 | $3.51 |
| USD/shares | $18.10 – $18.65* | — | $10.46G | $8.84G | $4.77G | $13.97G | $24.39 | $13.64 | $7.17 | $7.40 | $10.15 | $5.86 | $3.74 | $5.08 | $5.37 | $5.15 | $4.39 | $4.54 | $4.28 | $3.57 | $3.38 |
| shares | — | — | 83.2M | 83.9M | 87.1M | 91.1M | 96.7M | 113.26M | 113.96M | 118.03M | 119.19M | 119.31M | 115M | 98.71M | 104.99M | 111.39M | 116.4M | 119.89M | 125.01M | 127.69M | — |
| shares | — | — | 83.8M | 84.4M | 87.6M | 91.6M | 97.5M | 114.07M | 114.77M | 119.43M | 120.94M | 121.41M | 117.1M | 100.57M | 106.86M | 113.37M | 118.5M | 122.69M | 126.99M | 130.14M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.41B in buybacks, $933M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.31×
Peer median 6.13×
EV/EBIT
22.13×
Peer median 39.66×
P/E (TTM)
27.95×
Peer median 34.28×
Peer medians compare against the 23 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $10,876,500,000 | $10,144,300,000 | $9,415,100,000 | $9,203,500,000 | $10,363,600,000 | $9,253,400,000 | $7,000,100,000 | — |
| Biopharma Laboratory Services | $3,098,200,000 | $2,922,600,000 | $2,774,200,000 | $2,697,300,000 | — | — | — | — |
| Covance Drug Development | — | — | — | — | — | — | — | $4,313,100,000 |
| Drug Development | — | — | — | — | $2,860,700,000 | $4,877,700,000 | $4,578,100,000 | — |
| LabCorp Diagnostics | — | — | — | — | — | — | — | $7,030,800,000 |
By Geography (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| North America | $13,093,700,000 | $11,525,300,000 | — |
| Europe | $2,050,800,000 | $1,512,200,000 | — |
| Other Countries | $976,400,000 | $941,000,000 | $1,199,700,000 |
| Canada | — | — | $333,300,000 |
| Switzerland | — | — | $532,900,000 |
| United Kingdom | — | — | $507,900,000 |
| United States | — | — | $8,981,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $1,779,900,000 | $1,606,300,000 | $1,591,300,000 | $2,025,500,000 | $3,205,600,000 | $2,801,300,000 | $1,086,000,000 | $1,166,700,000 |
| Biopharma Laboratory Services | $498,500,000 | $458,900,000 | $396,300,000 | $389,100,000 | — | — | — | — |
| Corporate | -$482,200,000 | -$670,800,000 | -$644,100,000 | -$468,800,000 | -$404,500,000 | -$299,400,000 | -$167,300,000 | -$144,600,000 |
| Drug Development | — | — | $396,300,000 | $389,100,000 | $501,000,000 | $721,600,000 | $411,500,000 | $303,600,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diagnostics | 16.4% | 15.8% | 16.9% | 22% | 30.9% | 30.3% | 15.5% |
| Biopharma Laboratory Services | 16.1% | 15.7% | 14.3% | 14.4% | — | — | — |
| Drug Development | — | — | — | — | 17.5% | 14.8% | 9% |
Key facts
CIK
920148
CUSIP
504922105
13F (30d)
775 filings
766 filers
Visit website
Investor relations